AMPHASTAR PHARMACEUTICALS IN (AMPH) Fundamental Analysis & Valuation

NASDAQ:AMPH • US03209R1032

Current stock price

21.88 USD
-0.08 (-0.36%)
At close:
21.88 USD
0 (0%)
After Hours:

This AMPH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. AMPH Profitability Analysis

1.1 Basic Checks

  • AMPH had positive earnings in the past year.
  • In the past year AMPH had a positive cash flow from operations.
  • AMPH had positive earnings in each of the past 5 years.
  • AMPH had a positive operating cash flow in each of the past 5 years.
AMPH Yearly Net Income VS EBIT VS OCF VS FCFAMPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M

1.2 Ratios

  • AMPH has a Return On Assets of 6.02%. This is amongst the best in the industry. AMPH outperforms 86.91% of its industry peers.
  • AMPH has a better Return On Equity (12.44%) than 86.91% of its industry peers.
  • AMPH's Return On Invested Capital of 7.81% is amongst the best of the industry. AMPH outperforms 86.91% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for AMPH is below the industry average of 13.08%.
Industry RankSector Rank
ROA 6.02%
ROE 12.44%
ROIC 7.81%
ROA(3y)8.41%
ROA(5y)9.36%
ROE(3y)18.58%
ROE(5y)17.39%
ROIC(3y)10.83%
ROIC(5y)11.23%
AMPH Yearly ROA, ROE, ROICAMPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15 20

1.3 Margins

  • AMPH has a Profit Margin of 13.63%. This is amongst the best in the industry. AMPH outperforms 86.39% of its industry peers.
  • AMPH's Profit Margin has improved in the last couple of years.
  • With an excellent Operating Margin value of 19.50%, AMPH belongs to the best of the industry, outperforming 87.43% of the companies in the same industry.
  • AMPH's Operating Margin has improved in the last couple of years.
  • AMPH has a Gross Margin of 49.46%. This is in the better half of the industry: AMPH outperforms 63.35% of its industry peers.
  • In the last couple of years the Gross Margin of AMPH has grown nicely.
Industry RankSector Rank
OM 19.5%
PM (TTM) 13.63%
GM 49.46%
OM growth 3Y-3.26%
OM growth 5Y44.05%
PM growth 3Y-9.39%
PM growth 5Y102.5%
GM growth 3Y-0.28%
GM growth 5Y3.84%
AMPH Yearly Profit, Operating, Gross MarginsAMPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. AMPH Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AMPH is still creating some value.
  • The number of shares outstanding for AMPH has been reduced compared to 1 year ago.
  • AMPH has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, AMPH has an improved debt to assets ratio.
AMPH Yearly Shares OutstandingAMPH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
AMPH Yearly Total Debt VS Total AssetsAMPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 2.35 indicates that AMPH is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 2.35, AMPH is in the better half of the industry, outperforming 60.73% of the companies in the same industry.
  • AMPH has a debt to FCF ratio of 5.13. This is a neutral value as AMPH would need 5.13 years to pay back of all of its debts.
  • AMPH's Debt to FCF ratio of 5.13 is amongst the best of the industry. AMPH outperforms 83.77% of its industry peers.
  • AMPH has a Debt/Equity ratio of 0.77. This is a neutral value indicating AMPH is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.77, AMPH is doing worse than 72.77% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF 5.13
Altman-Z 2.35
ROIC/WACC0.88
WACC8.84%
AMPH Yearly LT Debt VS Equity VS FCFAMPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • AMPH has a Current Ratio of 4.02. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of AMPH (4.02) is comparable to the rest of the industry.
  • AMPH has a Quick Ratio of 2.90. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 2.90, AMPH perfoms like the industry average, outperforming 51.83% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.02
Quick Ratio 2.9
AMPH Yearly Current Assets VS Current LiabilitesAMPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. AMPH Growth Analysis

3.1 Past

  • The earnings per share for AMPH have decreased strongly by -15.80% in the last year.
  • AMPH shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 38.40% yearly.
  • AMPH shows a decrease in Revenue. In the last year, the revenue decreased by -1.65%.
  • AMPH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.53% yearly.
EPS 1Y (TTM)-15.8%
EPS 3Y18.16%
EPS 5Y38.4%
EPS Q2Q%-20.65%
Revenue 1Y (TTM)-1.65%
Revenue growth 3Y12.99%
Revenue growth 5Y15.53%
Sales Q2Q%-1.83%

3.2 Future

  • The Earnings Per Share is expected to decrease by -1.20% on average over the next years.
  • Based on estimates for the next years, AMPH will show a small growth in Revenue. The Revenue will grow by 4.48% on average per year.
EPS Next Y3.08%
EPS Next 2Y4.66%
EPS Next 3Y4.96%
EPS Next 5Y-1.2%
Revenue Next Year3.78%
Revenue Next 2Y4.21%
Revenue Next 3Y3.87%
Revenue Next 5Y4.48%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AMPH Yearly Revenue VS EstimatesAMPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
AMPH Yearly EPS VS EstimatesAMPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

8

4. AMPH Valuation Analysis

4.1 Price/Earnings Ratio

  • AMPH is valuated cheaply with a Price/Earnings ratio of 6.73.
  • Based on the Price/Earnings ratio, AMPH is valued cheaper than 95.29% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.64. AMPH is valued rather cheaply when compared to this.
  • Based on the Price/Forward Earnings ratio of 6.53, the valuation of AMPH can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, AMPH is valued cheaply inside the industry as 94.24% of the companies are valued more expensively.
  • AMPH is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.36, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 6.73
Fwd PE 6.53
AMPH Price Earnings VS Forward Price EarningsAMPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AMPH indicates a rather cheap valuation: AMPH is cheaper than 95.81% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, AMPH is valued cheaper than 95.29% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.19
EV/EBITDA 6.03
AMPH Per share dataAMPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The excellent profitability rating of AMPH may justify a higher PE ratio.
PEG (NY)2.19
PEG (5Y)0.18
EPS Next 2Y4.66%
EPS Next 3Y4.96%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AMPH Dividend Analysis

5.1 Amount

  • AMPH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AMPH Fundamentals: All Metrics, Ratios and Statistics

AMPHASTAR PHARMACEUTICALS IN

NASDAQ:AMPH (5/1/2026, 8:09:31 PM)

After market: 21.88 0 (0%)

21.88

-0.08 (-0.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength67.7
Industry Growth15.53
Earnings (Last)02-26
Earnings (Next)05-07
Inst Owners76.54%
Inst Owner Change0.09%
Ins Owners10.07%
Ins Owner Change4.03%
Market Cap974.32M
Revenue(TTM)719.89M
Net Income(TTM)98.09M
Analysts76.92
Price Target27.39 (25.18%)
Short Float %12.4%
Short Ratio6.99
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.91%
Min EPS beat(2)-22.4%
Max EPS beat(2)10.58%
EPS beat(4)3
Avg EPS beat(4)1.57%
Min EPS beat(4)-22.4%
Max EPS beat(4)12.46%
EPS beat(8)5
Avg EPS beat(8)2.84%
EPS beat(12)8
Avg EPS beat(12)9.98%
EPS beat(16)11
Avg EPS beat(16)14.27%
Revenue beat(2)1
Avg Revenue beat(2)-1.97%
Min Revenue beat(2)-5.76%
Max Revenue beat(2)1.82%
Revenue beat(4)1
Avg Revenue beat(4)-1.93%
Min Revenue beat(4)-5.76%
Max Revenue beat(4)1.82%
Revenue beat(8)2
Avg Revenue beat(8)-1.61%
Revenue beat(12)5
Avg Revenue beat(12)-0.48%
Revenue beat(16)8
Avg Revenue beat(16)-0.12%
PT rev (1m)-7.39%
PT rev (3m)-14.93%
EPS NQ rev (1m)-2.31%
EPS NQ rev (3m)-11.06%
EPS NY rev (1m)-0.84%
EPS NY rev (3m)-9.82%
Revenue NQ rev (1m)-0.4%
Revenue NQ rev (3m)0.07%
Revenue NY rev (1m)-0.27%
Revenue NY rev (3m)-1.08%
Valuation
Industry RankSector Rank
PE 6.73
Fwd PE 6.53
P/S 1.35
P/FCF 8.19
P/OCF 6.24
P/B 1.24
P/tB 4.37
EV/EBITDA 6.03
EPS(TTM)3.25
EY14.85%
EPS(NY)3.35
Fwd EY15.31%
FCF(TTM)2.67
FCFY12.21%
OCF(TTM)3.51
OCFY16.02%
SpS16.17
BVpS17.71
TBVpS5
PEG (NY)2.19
PEG (5Y)0.18
Graham Number35.9908 (64.49%)
Profitability
Industry RankSector Rank
ROA 6.02%
ROE 12.44%
ROCE 9.54%
ROIC 7.81%
ROICexc 9.67%
ROICexgc 18.47%
OM 19.5%
PM (TTM) 13.63%
GM 49.46%
FCFM 16.53%
ROA(3y)8.41%
ROA(5y)9.36%
ROE(3y)18.58%
ROE(5y)17.39%
ROIC(3y)10.83%
ROIC(5y)11.23%
ROICexc(3y)13.25%
ROICexc(5y)14.34%
ROICexgc(3y)28.69%
ROICexgc(5y)24.19%
ROCE(3y)13.23%
ROCE(5y)13.72%
ROICexgc growth 3Y-3.07%
ROICexgc growth 5Y50.2%
ROICexc growth 3Y-19.69%
ROICexc growth 5Y34.74%
OM growth 3Y-3.26%
OM growth 5Y44.05%
PM growth 3Y-9.39%
PM growth 5Y102.5%
GM growth 3Y-0.28%
GM growth 5Y3.84%
F-Score6
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF 5.13
Debt/EBITDA 3.09
Cap/Depr 65.49%
Cap/Sales 5.16%
Interest Coverage 6.05
Cash Conversion 79.21%
Profit Quality 121.3%
Current Ratio 4.02
Quick Ratio 2.9
Altman-Z 2.35
F-Score6
WACC8.84%
ROIC/WACC0.88
Cap/Depr(3y)81.11%
Cap/Depr(5y)91.09%
Cap/Sales(3y)5.56%
Cap/Sales(5y)5.56%
Profit Quality(3y)111.67%
Profit Quality(5y)103.97%
High Growth Momentum
Growth
EPS 1Y (TTM)-15.8%
EPS 3Y18.16%
EPS 5Y38.4%
EPS Q2Q%-20.65%
EPS Next Y3.08%
EPS Next 2Y4.66%
EPS Next 3Y4.96%
EPS Next 5Y-1.2%
Revenue 1Y (TTM)-1.65%
Revenue growth 3Y12.99%
Revenue growth 5Y15.53%
Sales Q2Q%-1.83%
Revenue Next Year3.78%
Revenue Next 2Y4.21%
Revenue Next 3Y3.87%
Revenue Next 5Y4.48%
EBIT growth 1Y-31.65%
EBIT growth 3Y9.31%
EBIT growth 5Y66.42%
EBIT Next Year6.27%
EBIT Next 3Y3.07%
EBIT Next 5YN/A
FCF growth 1Y-30.96%
FCF growth 3Y22.23%
FCF growth 5Y38.43%
OCF growth 1Y-26.84%
OCF growth 3Y20.52%
OCF growth 5Y22.21%

AMPHASTAR PHARMACEUTICALS IN / AMPH Fundamental Analysis FAQ

What is the fundamental rating for AMPH stock?

ChartMill assigns a fundamental rating of 6 / 10 to AMPH.


What is the valuation status for AMPH stock?

ChartMill assigns a valuation rating of 8 / 10 to AMPHASTAR PHARMACEUTICALS IN (AMPH). This can be considered as Undervalued.


What is the profitability of AMPH stock?

AMPHASTAR PHARMACEUTICALS IN (AMPH) has a profitability rating of 8 / 10.


Can you provide the financial health for AMPH stock?

The financial health rating of AMPHASTAR PHARMACEUTICALS IN (AMPH) is 7 / 10.